814 related articles for article (PubMed ID: 33082265)
1. Effect of IBD medications on COVID-19 outcomes: results from an international registry.
Ungaro RC; Brenner EJ; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
Gut; 2021 Apr; 70(4):725-732. PubMed ID: 33082265
[TBL] [Abstract][Full Text] [Related]
2. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
Brenner EJ; Ungaro RC; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
Gastroenterology; 2020 Aug; 159(2):481-491.e3. PubMed ID: 32425234
[TBL] [Abstract][Full Text] [Related]
3. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
Izadi Z; Brenner EJ; Mahil SK; Dand N; Yiu ZZN; Yates M; Ungaro RC; Zhang X; Agrawal M; Colombel JF; Gianfrancesco MA; Hyrich KL; Strangfeld A; Carmona L; Mateus EF; Lawson-Tovey S; Klingberg E; Cuomo G; Caprioli M; Cruz-Machado AR; Mazeda Pereira AC; Hasseli R; Pfeil A; Lorenz HM; Hoyer BF; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Seet AM; Al Emadi S; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Isnardi CA; Quintana R; Soriano ER; Hsu TY; D'Silva KM; Sparks JA; Patel NJ; Xavier RM; Marques CDL; Kakehasi AM; Flipo RM; Claudepierre P; Cantagrel A; Goupille P; Wallace ZS; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Griffiths CEM; Barker JN; Smith CH; Yazdany J; Kappelman MD; ;
JAMA Netw Open; 2021 Oct; 4(10):e2129639. PubMed ID: 34661663
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
Agrawal M; Zhang X; Brenner EJ; Ungaro RC; Kappelman MD; Colombel JF
J Crohns Colitis; 2021 Nov; 15(11):1877-1884. PubMed ID: 33884425
[TBL] [Abstract][Full Text] [Related]
5. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
Stobaugh DJ; Deepak P
Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
[TBL] [Abstract][Full Text] [Related]
6. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
[TBL] [Abstract][Full Text] [Related]
7. Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry.
Agrawal M; Brenner EJ; Zhang X; Colombel JF; Kappelman MD; Ungaro RC; ; Gearry RB; Kalpan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE
J Crohns Colitis; 2021 May; 15(5):860-863. PubMed ID: 33232456
[TBL] [Abstract][Full Text] [Related]
8. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
Chupin A; Perduca V; Meyer A; Bellanger C; Carbonnel F; Dong C
Aliment Pharmacol Ther; 2020 Oct; 52(8):1289-1297. PubMed ID: 32840893
[TBL] [Abstract][Full Text] [Related]
9. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
10. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease.
Otten AT; Bourgonje AR; Horinga PP; van der Meulen HH; Festen EAM; van Dullemen HM; Weersma RK; van Leer-Buter CC; Dijkstra G; Visschedijk MC
Front Immunol; 2022; 13():920333. PubMed ID: 35865529
[TBL] [Abstract][Full Text] [Related]
11. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
[TBL] [Abstract][Full Text] [Related]
12. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
Kirchgesner J; Lemaitre M; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
Gastroenterology; 2018 Aug; 155(2):337-346.e10. PubMed ID: 29655835
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry.
Queiroz NSF; Martins CA; Quaresma AB; Hino AAF; Steinwurz F; Ungaro RC; Kotze PG
J Gastroenterol Hepatol; 2021 Nov; 36(11):3033-3040. PubMed ID: 34151470
[TBL] [Abstract][Full Text] [Related]
14. Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases.
Brenner EJ; Pigneur B; Focht G; Zhang X; Ungaro RC; Colombel JF; Turner D; Kappelman MD; Ruemmele FM
Clin Gastroenterol Hepatol; 2021 Feb; 19(2):394-396.e5. PubMed ID: 33059040
[TBL] [Abstract][Full Text] [Related]
15. Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study.
Meyer A; Semenzato L; Zureik M; Weill A; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2021 Jul; 54(2):160-166. PubMed ID: 34110040
[TBL] [Abstract][Full Text] [Related]
16. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD.
Kakuta Y; Naito T; Onodera M; Kuroha M; Kimura T; Shiga H; Endo K; Negoro K; Kinouchi Y; Shimosegawa T
Pharmacogenomics J; 2016 Jun; 16(3):280-5. PubMed ID: 26076924
[TBL] [Abstract][Full Text] [Related]
17. Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions.
Soh JS; Yun WJ; Kim KJ; Won CH; Park SH; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Kim JH
Inflamm Bowel Dis; 2015 Apr; 21(4):832-9. PubMed ID: 25789922
[TBL] [Abstract][Full Text] [Related]
18. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
Tripathi K; Godoy Brewer G; Thu Nguyen M; Singh Y; Saleh Ismail M; Sauk JS; Parian AM; Limketkai BN
Inflamm Bowel Dis; 2022 Aug; 28(8):1265-1279. PubMed ID: 34718595
[TBL] [Abstract][Full Text] [Related]
20. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]